Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX (2 Cef)

This study has been completed.
Sponsor:
Collaborator:
Parexel
Information provided by (Responsible Party):
B. Braun Medical Inc.
ClinicalTrials.gov Identifier:
NCT01121354
First received: May 10, 2010
Last updated: July 15, 2013
Last verified: July 2013
  Purpose

The purpose of this study is to demonstrate the safety and pharmacokinetics of Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System to Cefazolin 1.5g for Injection USP and Dextrose Injection USP in daily doses of 6g in healthy adult subjects for 11 days of administration.


Condition Intervention Phase
Infection
Drug: Cefazolin 2g for Injection USP and Dextrose Injection USP
Drug: Cefazolin 1.5g
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Multiple-Dose Two-Arm Study to Evaluate the PK and Safety of Cefazolin 2g for Inj. USP and Dextrose Inj. USP in the DUPLEX® Drug Delivery System and Cefazolin for Inj. 1.5g in Daily Doses of 6g in Healthy Adult Subjects

Resource links provided by NLM:


Further study details as provided by B. Braun Medical Inc.:

Primary Outcome Measures:
  • To evaluate the pharmacokinetics of an intravenous infusion of Cefazolin 2g in healthy adult subjects at an infusion rate of 50 ml over 15 minutes, and Cefazolin 1.5g in a similar population of healthy adult subjects [ Time Frame: PK is evaluated on Days 1 and 11 of infusion therapy ] [ Designated as safety issue: No ]
    The primary objective is to evaluate the pharmacokinetics of an intravenous infusion of Cefazolin 2g for injection USP and Dextrose injection USP in healthy adult subjects at an infusion rate of 50 ml over 15 minutes, and Cefazolin 1.5g for injection USP and Dextrose injection USP in a similar population of healthy adult subjects.


Secondary Outcome Measures:
  • To evaluate the safety of cefazolin 2g injection in total daily doses of 6g over 11 days of administration in healthy volunteers [ Time Frame: Varies, over 11 days of infusion therapy ] [ Designated as safety issue: Yes ]
    • Hematology(CBC): Hb, Hct, RBC count, RBC indices, RBC morphology, platelet count, WBC count, and differential WBC
    • Clinical Chemistry: Sodium, potassium, chloride, Co2, glucose, ALT, AST, alkaline phosphatase, serum albumin, total bilirubin, blood urea nitrogen, and creatinine
    • Urinalysis: specific gravity, protein, blood, nitrates, leukocyte esterase, glucose, ketone, appearance, pH
    • Urine drug and blood alcohol tests
    • C. difficile
    • ECG
    • Vital signs: temperature, blood pressure, heart rate, and respiratory rate
    • Adverse Events
    • Physical exams


Enrollment: 24
Study Start Date: December 2009
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cefazolin 2g (Test) Drug: Cefazolin 2g for Injection USP and Dextrose Injection USP
Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur three times per day (t.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
Other Name: Cefazolin 2g in DUPLEX (50ml)
Active Comparator: Cefazolin 1.5g (Control) Drug: Cefazolin 1.5g
Cefazolin 1.5g for Injection USP and Dextrose Injection USP in a pharmacy-prepared container. Administration will occur four times per day (q.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
Other Name: Cefazolin 1.5g (50ml)

Detailed Description:

B. Braun Medical Inc. intends to conduct human PK studies and obtain marketing approval for Cefazolin 2g in the United States with identical indications of those already approved for the 1g strength. A pharmacokinetic study will be conducted with the Cefazolin 2g product manufactured by B. Braun Medical Inc. Cefazolin 1.5g dose will be prepared using 10g Cefazolin pharmacy bulk with 5% Dextrose. The clinical study proposed in this protocol is designed to evaluate the pharmacokinetic characteristics of 2g and 1.5g Cefazolin in Dextrose in healthy subjects at the maximum recommended infusion dose of 6g per day per FDA's recommendation.

The study is designed to simulate clinical practice and overall experience with cephalosporin administration. Cefazolin may be reconstituted with dextrose (or a number of other diluents as recommended in the innovator's package insert) in order to achieve an osmolality appropriate for intravenous infusion.

According to B. Braun's approved package insert for Cefazolin 1g, the maximum dose of 1.5g Cefazolin for Injection USP and Dextrose Injection USP is 1.5 grams every 6 hours for severe, life-threatening infections. In rare instances, doses of up to 12 grams of Cefazolin per day have been used. Lower doses are stated in the B. Braun package insert.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy subjects, male and female
  • Age: 18 - 70 years (inclusive) at the time of screening.
  • Females of non-child bearing potential (surgically sterile [hysterectomy or bilateral tubal ligation] or post-menopausal >= 1 year with follicle stimulating hormone [FSH] > 40 U/L).
  • Healthy, determined by pre-study medical evaluation (medical history, physical examination, vital signs, electrocardiogram, and clinical laboratory evaluations).
  • Subject voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved informed consent and the Health Insurance Portability and Accountability Act (HIPAA) Authorization prior to performing any of the screening procedures.

Exclusion Criteria:

  • Known allergy or hypersensitivity to beta-lactam/cephalosporin antibiotics, corn products or any of the other ingredients of the Investigational Products
  • Subjects with impaired renal function based on the Cockcroft-Gault formula using actual body weight, i.e. estimated creatinine clearance <= 80 mL/min (performed at Screening only)
  • Body Mass Index (BMI) < 20.0 or > 30.0 kg/m^2
  • Body Weight < 50.0 kg
  • White Blood Count (WBC) < 3.5 x10^3/uL or > ULN
  • absolute neutrophil count (ANC) < 1.5 x10^3/uL or > ULN
  • Alarine aminotransferase and aspartate aminotransferase > upper limit of normal
  • Other laboratory tests that are outside the normal limits, considered by the investigator, to be clinically significant.
  • Use of any medication on a chronic basis.
  • Takes any medication which interferes with the study drug or study procedures including aminoglycosides, anticoagulants, and probenecids.
  • Use of over the counter (OTC) medications (including vitamins), prescription medications, or herbal remedies from 14 days prior to Day -1 until end of study. By exception, acetaminophen <= 1 gram per day is permitted.
  • Tobacco use during the last 2 months prior to enrollment.
  • Positive screening test for Hepatitis B surface antigen, Hepatitis C antibody, or human immunodeficiency virus (HIV) antibody.
  • Positive urine drug test (cocaine, amphetamines, barbiturates, opiates, benzodiazepines, cannabinoids, etc.) at Screening or Day -1
  • Positive blood test for ethanol at screening or Day -1.
  • At screening, the subject has a clinically relevant ECG change, as assessed by the PI or designee.
  • Concurrent acute or chronic infections (e.g. viral infections, except chronic recurrent herpes infections)
  • History of or ongoing alcohol abuse or drug abuse (within last 2 years).
  • Received an Investigational drug or device within 30 days of first dose of study drug
  • Clinically relevant medical conditions which are likely to interfere with the evaluation of the trial drug, e.g. COPD, metabolic disorders (such as clinical and sub-clinical diabetes mellitus), history of malignant diseases (within last 5 years), autoimmune diseases, and cardiovascular disease
  • Any planned medical intervention or personal event that might interfere with the ability to comply with the study requirements
  • Any condition that, in the opinion of the principal investigator, would compromise the safety of the patient or the quality of the data
  • Unable or unwilling to adhere to the study-specified procedures and restrictions
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01121354

Locations
United States, Maryland
PAREXEL Early Phase Clinical Unit
Baltimore, Maryland, United States, 21225
Sponsors and Collaborators
B. Braun Medical Inc.
Parexel
Investigators
Principal Investigator: Azra Hussaini, MD PAREXEL Early Phase Clinical Unit
  More Information

Publications:
Responsible Party: B. Braun Medical Inc.
ClinicalTrials.gov Identifier: NCT01121354     History of Changes
Other Study ID Numbers: HC-G-H-0906
Study First Received: May 10, 2010
Last Updated: July 15, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by B. Braun Medical Inc.:
Cefazolin
Caphalosporin
antibiotic
gram positive
Infection control

Additional relevant MeSH terms:
Cefazolin
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 22, 2014